Genmab | GEN - Net Income

Stock Price
2,020.00
Daily Change
-77.00 -3.67%
Monthly
0.50%
Yearly
44.03%
Q1 Forecast
1,920.90

Genmab reported DKK336M in Net Income for its fiscal quarter ending in June of 2025.





Net Income Change Date
Agios Pharmaceuticals USD -103.43M 8.59M Sep/2025
Almirall EUR 26.58M 31.82M Jun/2025
Amarin USD -7.74M 6.4M Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
argenx SE USD 344.26M 98.9M Sep/2025
AstraZeneca USD 2.53B 83M Sep/2025
Bayer EUR -963M 764M Sep/2025
BioMarin Pharmaceutical USD -30.74M 271.28M Sep/2025
Demant DKK 427M 690M Dec/2025
Exelixis USD 193.58M 8.73M Sep/2025
Fresenius Medical Care EUR 274.8M 49.8M Sep/2025
Galapagos EUR -202.11M 96.36M Sep/2025
Genmab DKK 336M 141M Jun/2025
GlaxoSmithKline GBP 2.01B 570M Sep/2025
GN Store Nord DKK 73M 92M Sep/2025
GRIFOLS EUR 126.96M 9.9M Sep/2025
Hikma Pharmaceutical USD 119M 14M Jun/2025
Insmed USD -370.02M 48.34M Sep/2025
Lonza CHF 307M 22M Dec/2024
Merck EUR 902M 250M Sep/2025
Novartis USD 3.93B 96M Sep/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
UCB EUR 857M 649M Dec/2024